ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 567

Non-Surgical Periodontal Therapy Plus Short-Term Antibiotic Treatment May Improve Clinical Disease Activity: A Pilot Study in Difficult to Treat Rheumatoid Arthritis

Burkhard Moeller1, Philip Bender2, Sigrun Eick2, Kim Midwood3, Jan Potempa4, Stephan Reichenbach5, Anja Schwenzer3, Peter M. Villiger6 and Alicia Wong3, 1Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, 2School of Dental Medicine, University of Bern, Bern, Switzerland, 3Kennedy Institute for Rheumatology, Oxford University, Oxford, United Kingdom, 4Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland, 5Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, 6University of Bern, Bern, Switzerland

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Anti-citrullinated protein/peptide antibodies (ACPA) and rheumatoid arthritis (RA), Disease Activity, Intervention, Periodontitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Autoimmunity against citrullinated peptides is a hallmark of rheumatoid arthritis (RA). Chronic periodontitis (CP) is a known major source of citrullinated peptides. Here, we investigated potential associations between the treatment of CP, the reduction pathogenic periodontal microbes, the autoantibody repertoire and RA disease activity.
Methods: We evaluated ten patients with DAS28>=4.2 for the presence and severity of CP. All patients had active disease and were positive for rheumatoid factor and anti-cyclic citrullinated peptide antibody (ACPA). Each had an inadequate response to at least two conventional and two biological disease modifying anti-rheumatic drugs. Periodontal scaling and root planing (SRP) was performed in conjunction with one week of amoxicillin and metronidazole therapy, if significant CP was indicated by clinical attachment level (CAL) loss ≥5mm at ≥2 separate sites.
The primary outcome was mean DAS28 improvement >1.2 from baseline to month 3, corresponding to good clinical response. Secondary clinical outcomes included periodontal pocket depth (PD), CAL, and bleeding on probing (BOP). The presence of major periodontal pathogens was assessed by semiquantitative polymerase chain reaction in the subgingival biofilm at baseline, month 3 and 6. Sera were longitudinally tested for antibodies against native and citrullinated peptides from enolase, fibrinogen, vimentin, and tenascin-C.
Results: Eight patients had CP requiring treatment. In these patients, DAS28 improved upon SRP by mean (+/- SD) 0.74 +/- 0.93, p=0.049, thereby failing the predefined significance at a group level. Nevertheless, moderate and transient DAS28 response >0.6 at month three was achieved in three patients, and prolonged good clinical response was observed in a fourth patient at month 3 and 6. The clinical signs of CP improved in parallel, PD by 1.8 +/- 1.5 mm (mean+/-SD), p=0.018, CAL by 0.7 +/- 0.6 mm, p=0.051, and BOP by 36 +/- 24%, p=0.018. Furthermore, the microbial burden was significantly reduced upon SRP in the biofilm for the following bacteria: P. gingivalis, Treponema denticola and Tannerella forsythia, p<0.05 for all. However, the serum concentrations of all tested autoantibodies remained unchanged at group level, and the changes in the microbiota and titers of autoantibodies could not specifically be associated with improvement of arthritis symptoms in individual patients.
Conclusion: Successful treatment of CP reduced the burden of specific microbial species in the periodontal biofilm, and improvement of clinical RA disease activity could be observed in individual patients. This finding could support the hypothesis of RA inflammation being permanently triggered by chronic periodontal infections. However, clinical responses in this small interventional pilot study did not track back to changes in the microbiota or in the antigen specific immune response, suggesting patient improvement is not directly linked to these aspects of disease.


Disclosure: B. Moeller, None; P. Bender, None; S. Eick, None; K. Midwood, None; J. Potempa, None; S. Reichenbach, None; A. Schwenzer, None; P. M. Villiger, None; A. Wong, None.

To cite this abstract in AMA style:

Moeller B, Bender P, Eick S, Midwood K, Potempa J, Reichenbach S, Schwenzer A, Villiger PM, Wong A. Non-Surgical Periodontal Therapy Plus Short-Term Antibiotic Treatment May Improve Clinical Disease Activity: A Pilot Study in Difficult to Treat Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/non-surgical-periodontal-therapy-plus-short-term-antibiotic-treatment-may-improve-clinical-disease-activity-a-pilot-study-in-difficult-to-treat-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/non-surgical-periodontal-therapy-plus-short-term-antibiotic-treatment-may-improve-clinical-disease-activity-a-pilot-study-in-difficult-to-treat-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology